In this issue of Blood , Kataoka et al 1 leverage their landscape of adult T-cell leukemia/lymphoma (ATL) to define associations between outcome and specific genetic alterations. 2 They identify gene alterations in both high-grade and low-grade disease that correlate with outcome. Future studies are needed to refine and validate this clinicogenetic classification of ATL. Once validated, prospective studies should assess whether patients with poor-risk disease benefit from alternative strategies and whether those with low-risk disease can achieve long-term survival with less intensive treatment.

中文翻译：

---

ATL 中的临床遗传风险模型

在本期血液中，Kataoka 等人 1 利用他们对成人 T 细胞白血病/淋巴瘤 (ATL) 的研究来定义结果与特定基因改变之间的关联。2 他们确定了与结果相关的高级别和低级别疾病的基因改变。需要进一步的研究来完善和验证 ATL 的这种临床遗传学分类。一旦得到验证，前瞻性研究应评估低危患者是否可以从替代策略中获益，以及低危患者是否可以通过较少的强化治疗实现长期生存。